In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lundbeck licenses two Teva Parkinson's disease drugs

Executive Summary

Danish CNS drug developer H. Lundbeck in collaboration with Teva (Israel's largest pharmaceutical company), will co-develop the latter's Parkinson's disease drugs: the Phase III Rasagiline and TV 1203, in Phase II. Lundbeck will get exclusive European marketing rights from Teva, which will retain rights in all other territories worldwide.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register